Compass Therapeutics, Inc. (NASDAQ:CMPX) Receives $12.23 Average Price Target from Brokerages

Shares of Compass Therapeutics, Inc. (NASDAQ:CMPX) have been assigned an average rating of “Moderate Buy” from the fifteen analysts that are currently covering the company, MarketBeat.com reports. One analyst has rated the stock with a sell rating, thirteen have given a buy rating and one has assigned a strong buy rating to the company. The average 12-month target price among brokers that have issued ratings on the stock in the last year is $12.2308.

A number of equities research analysts recently commented on the stock. Leerink Partnrs upgraded shares of Compass Therapeutics to a “strong-buy” rating in a report on Wednesday, November 26th. Cantor Fitzgerald initiated coverage on shares of Compass Therapeutics in a research report on Wednesday, December 3rd. They issued an “overweight” rating on the stock. Canaccord Genuity Group assumed coverage on shares of Compass Therapeutics in a research note on Wednesday, December 3rd. They set a “buy” rating and a $10.00 price objective for the company. Citizens Jmp initiated coverage on shares of Compass Therapeutics in a report on Wednesday, December 3rd. They set a “market outperform” rating and a $10.00 target price for the company. Finally, Wall Street Zen raised Compass Therapeutics from a “sell” rating to a “hold” rating in a research note on Saturday, November 8th.

Hedge Funds Weigh In On Compass Therapeutics

Several hedge funds have recently made changes to their positions in the business. Suvretta Capital Management LLC raised its holdings in shares of Compass Therapeutics by 97.2% during the third quarter. Suvretta Capital Management LLC now owns 14,101,159 shares of the company’s stock valued at $49,354,000 after acquiring an additional 6,951,666 shares in the last quarter. Vivo Capital LLC increased its position in Compass Therapeutics by 57.9% during the 3rd quarter. Vivo Capital LLC now owns 9,545,466 shares of the company’s stock valued at $33,409,000 after purchasing an additional 3,502,000 shares during the period. Balyasny Asset Management L.P. purchased a new position in Compass Therapeutics during the 3rd quarter valued at $9,892,000. Millennium Management LLC raised its holdings in Compass Therapeutics by 280.4% in the 3rd quarter. Millennium Management LLC now owns 3,237,572 shares of the company’s stock worth $11,332,000 after purchasing an additional 2,386,367 shares in the last quarter. Finally, Vanguard Group Inc. lifted its position in shares of Compass Therapeutics by 45.6% in the 3rd quarter. Vanguard Group Inc. now owns 7,062,799 shares of the company’s stock worth $24,720,000 after purchasing an additional 2,212,794 shares during the period. 68.43% of the stock is owned by hedge funds and other institutional investors.

Compass Therapeutics Price Performance

CMPX opened at $5.25 on Monday. The stock’s 50 day simple moving average is $4.51 and its 200 day simple moving average is $3.49. The firm has a market cap of $933.77 million, a price-to-earnings ratio of -11.67 and a beta of 1.44. Compass Therapeutics has a 1 year low of $1.33 and a 1 year high of $5.86.

Compass Therapeutics (NASDAQ:CMPX) last announced its quarterly earnings data on Wednesday, November 5th. The company reported ($0.08) earnings per share for the quarter, beating the consensus estimate of ($0.14) by $0.06. As a group, sell-side analysts anticipate that Compass Therapeutics will post -0.36 EPS for the current year.

About Compass Therapeutics

Compass Therapeutics, Inc, a clinical-stage oncology-focused biopharmaceutical company, engages in developing antibody-based therapeutics to treat various human diseases in the United States. The company's lead product candidates include CTX-009, a bispecific antibody that blocks Delta-like ligand 4 a ligand of Notch-1, and vascular endothelial growth factor A signaling pathways, which are critical to angiogenesis and tumor vascularization; and CTX-471, an IgG4 monoclonal antibody that is an agonist of CD137, a key co-stimulatory receptor on immune cells.